Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have received a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $6.5417.

HUMA has been the subject of a number of research reports. Benchmark reduced their price target on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a report on Thursday, August 13th. HC Wainwright upped their price objective on shares of Humacyte from $3.00 to $4.00 and gave the company a “buy” rating in a report on Thursday, June 11th. TD Cowen reduced their target price on Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a research note on Wednesday, June 17th. BTIG Research reaffirmed a “buy” rating and issued a $2.00 target price on shares of Humacyte in a research report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research note on Wednesday, July 8th.

Humacyte Price Performance

Shares of HUMA opened at $0.60 on Friday. The firm has a market cap of $168.04 million, a PE ratio of -1.23 and a beta of 2.45. Humacyte has a 52-week low of $0.53 and a 52-week high of $2.55. The business’s 50 day moving average price is $0.67 and its two-hundred day moving average price is $0.86. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The company had revenue of $0.41 million for the quarter, compared to analyst estimates of $1.04 million. Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%. On average, equities analysts anticipate that Humacyte will post -0.4 EPS for the current year.

Hedge Funds Weigh In On Humacyte

A number of institutional investors have recently modified their holdings of HUMA. Geode Capital Management LLC lifted its holdings in shares of Humacyte by 33.4% in the 2nd quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock worth $6,163,000 after purchasing an additional 738,142 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Humacyte by 31.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 70,067 shares of the company’s stock valued at $146,000 after purchasing an additional 16,702 shares in the last quarter. Rhumbline Advisers increased its stake in Humacyte by 51.1% during the 2nd quarter. Rhumbline Advisers now owns 177,623 shares of the company’s stock valued at $371,000 after purchasing an additional 60,059 shares in the last quarter. Prudential Financial Inc. acquired a new position in Humacyte during the second quarter worth $28,000. Finally, Marshall Wace LLP raised its holdings in Humacyte by 5,308.2% during the second quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock worth $5,516,000 after buying an additional 2,590,394 shares during the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.